References
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69.
- El-Serag HB. Current concepts hepatocellular carcinoma. N Engl J Med. 2011;365:1118.
- El-Serag HB, Rudolph L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557.
- Cao G. Exploring risk factors of hepatitis B virus-associated hepatocellular carcinoma: prospective verse retrospective studies. J Gastroenterol. 2011;46:125.
- Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of Hepatitis B in China-Declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2009;27:6550.
- Chu C, Lok ASF. Clinical significance of hepatitis B virus genotypes. Hepatology. 2002;35:1274.
- Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res. 2001;52:113.
- Tian C, Stokowski RP, Kershenobich D, et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21.
- Stickel F, Buch S, Lau K, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology. 2011;53:86.
- Trepo E, Gustot T, Degre D, et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol. 2011;55:906.
- Zimmer V, Lammert F. Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol. 2011;25:269.
- Valenti L, Rumi M, Galmozzi E, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53:791.
- Trepo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54:60.
- Valenti L, Romeo S, Motta BM, et al. The rs2294918 K434E PNPLA3 polymorphism is associated with nonalcoholic fatty liver and steatohepatitis. Hepatology. 2013;581:246A.
- Pan Q, Zhang R, Wang Y, et al. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. WJG. 2015;21:8605.
- Tong J, Guo J, Hu J, et al. Correlation between patatin-like phospholipase domain-containing protein 3 gene polymorphisms and liver cirrhosis in a Chinese Han population with chronic hepatitis B. Hepat Mon. 2014;14:e18943.
- Kwak MS, Choi JW, Lee JS, et al. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. J Viral Hepatitis. 2011;18:e432.
- Rapti I, Dimon E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307.
- Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208.
- El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752.
- Pirazzi C, Adiels M, Burza MA, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012;57:1276.